Brain stimulation lifted quality of life, not mood

Chronic pain involves maladaptive changes in how the nervous system processes nociceptive signals, and transcranial electric stimulation has emerged as a non-invasive way to target them. Most trials have judged it on pain reduction alone, leaving open whether it changes the things patients care about most: quality of life, mood, sleep, fatigue and the ability to move and be active. Home-based delivery would also make the technique far more scalable than clinic-based sessions. This trial set out to test two stimulation modalities against sham on that broader set of outcomes, including objectively measured fitness and activity.

In a double-blind randomised controlled trial, 120 participants with chronic pain — 97 of them female, mean age 49.5 ± 8.7 years — were allocated to 15 home-based sessions of transcranial direct current stimulation over the primary motor cortex, transcranial alternating current stimulation over the dorsolateral prefrontal cortex, or sham stimulation. Assessment was multidimensional and repeated before, during and after treatment. Subjective measures covered quality of life, mood, fatigue, sleep quality and perceived physical fitness. Objective measures included field-based physical fitness tests and accelerometry to capture actual physical activity rather than self-report alone.

Both active stimulation modalities significantly improved quality of life relative to sham, with essentially no difference between motor-cortex direct current stimulation and prefrontal alternating current stimulation, and mean differences of -7.7 and -7.8 respectively. However, symptom-specific domains showed no differential effect against sham: mood, fatigue and sleep did not separate the groups. All three groups, sham included, increased physical activity during the intervention and improved physical function afterwards, which the authors interpret as evidence that contextual factors contributed. That pattern means the activity and fitness gains cannot be attributed to the stimulation itself.

The result supports a role for home-based transcranial stimulation in improving overall quality of life in chronic pain while complicating mechanistic explanations, since two different currents applied to two different brain regions produced near-identical benefit. The absence of any advantage on mood, fatigue or sleep, alongside improvements in every arm on activity and function, points to expectation, monitoring and engagement as plausible contributors. Open questions include which mechanism drives the quality-of-life change, whether the effect lasts beyond the treatment period, and how much of the broader improvement any trial participation would produce.

For readers with persistent pain, this is a reason to think home-delivered brain stimulation may improve overall quality of life, while being clear that it did not outperform a dummy device on mood, fatigue or sleep. The most instructive detail may be that everyone, including the sham group, became more active and physically fitter over the trial — a reminder of how strongly structure, attention and expectation shape outcomes in chronic pain. That does not make the quality-of-life finding meaningless, but it does argue for modest expectations and independent replication.